Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Richard

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Hematology (Amsterdam, Netherlands)|March 25, 2024
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native AsparaginaseMaria Agustina Perusini, Claire Andrews, Eshetu G Atenafu, et al.
Leukemia|November 14, 2019
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromesGuillermo Montalban-Bravo, Caleb A Class, Irene Ganan-Gomez, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Nature Methods|October 30, 2025
Annotating the genome at single-nucleotide resolution with DNA foundation modelsBernardo P de Almeida, Hugo Dalla-Torre, Guillaume Richard, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCTDonna Zhe Sian Eng, Fatima Khadadah, Maria Agustina Perusini, et al.
The Lancet. Haematology|October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trialGuillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
Blood Advances|January 3, 2024
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPNMarta B Davidson, James A Kennedy, Jose-Mario Capo-Chichi, et al.
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
NPJ Precision Oncology|August 1, 2024
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trialsAbdelrahman H Elsayed, Xueyuan Cao, Richard J Marrero, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Hematology (Amsterdam, Netherlands)|March 25, 2024
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native AsparaginaseMaria Agustina Perusini, Claire Andrews, Eshetu G Atenafu, et al.
Leukemia|November 14, 2019
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromesGuillermo Montalban-Bravo, Caleb A Class, Irene Ganan-Gomez, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Nature Methods|October 30, 2025
Annotating the genome at single-nucleotide resolution with DNA foundation modelsBernardo P de Almeida, Hugo Dalla-Torre, Guillaume Richard, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCTDonna Zhe Sian Eng, Fatima Khadadah, Maria Agustina Perusini, et al.
The Lancet. Haematology|October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trialGuillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
Blood Advances|January 3, 2024
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPNMarta B Davidson, James A Kennedy, Jose-Mario Capo-Chichi, et al.
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
NPJ Precision Oncology|August 1, 2024
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trialsAbdelrahman H Elsayed, Xueyuan Cao, Richard J Marrero, et al.
Pageof 4